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Objective: Smooth muscle cell proliferation is a major pathophysiologic factor in injury-induced neointimal hyperplasia
and recurrent stenosis. We have demonstrated that recombinant human thrombomodulin (rTM) inhibits thrombin-
induced arterial smooth muscle cell proliferation in vitro. The purpose of this study was to investigate the effect of rTM
on neointimal hyperplasia in vivo.
Methods: A rabbit femoral artery balloon injury model was used. Bilateral superficial femoral arteries were deendotheli-
alized with a 2F arterial embolectomy catheter. rTM (145 g/kg; 2.0 g/mL in circulation) or Tris-hydrochloride
vehicle control was administered intravenously during the procedure, then either discontinued (group A) or administered
twice daily for an additional 48 hours (group B). Rabbits were euthanized at 4 days and at 1, 2, and 4 weeks, and femoral
artery specimens were prepared with in situ perfusion fixation and paraffin embedding. Luminal, intima, media, and
whole artery areas were quantitated with digital imaging computerized planimetry. Intima-media and lumen–whole
artery ratios were calculated. The injury-induced inflammatory reaction was also evaluated with light microscopy,
scanning and transmission electron microscopy, and immunohistochemical and immunohistofluorescence staining.
Results: In the buffer control group, neointimal hyperplasia after femoral artery balloon injury was evident at 2 weeks, and
was pronounced at 4 weeks (P < .0001). Infusion of rTM significantly inhibited intimal hyperplasia at both 2 and 4 weeks
(P < .0001). In group A, rTM reduced the intima-media ratio by 27% and 39% at 2 and 4 weeks, respectively. Extended
administration of rTM (group B) resulted in inhibition of hyperplasia by 57% and 30% at 2 and 4 weeks, respectively, but
failed to reach significance compared with the shorter exposure. rTM infusion significantly inhibited thrombosis
(8.1-fold) compared with the buffer control group (P  .012). rTM had no significant effect on lumen area or
lumen–whole artery ratio, but treated arteries demonstrated significantly less compensatory dilatation (P  .045), as
measured by whole artery area in response to less intimal hyperplasia. rTM administration inhibited platelet adhesion and
inhibition of neutrophil infiltration to a degree that approached statistical significance (P  .0675).
Conclusions: Systemic intravenous administration of rTM significantly decreases neointimal hyperplasia and improves
patency in the rabbit femoral artery after balloon injury. In addition to exhibiting antithrombotic and antiproliferative
effects, rTM may also invoke an anti-inflammatory mechanism, and may alter vascular remodeling in a multidimensional
role to inhibit recurrent stenosis after arterial injury. (J Vasc Surg 2004;39:1074-83.)
Clinical Relevance: Results of angioplasty/stenting and surgical bypass remain hindered by restenosis and thrombosis.
Intravenous administration of thrombomodulin (TM) demonstrated a multifactorial effect resulting in significant
inhibition of neointimal hyperplasia and thrombus formation following balloon injury in a small-caliber artery model.
This, along with TM being an endogenous glycoprotein expressed on the luminal surface of the normal vessel wall, makes
it an attractive target to exploit in modulating the pathologic arterial response to injury with less risk of toxicity.
Administration of rTM intravenously has direct clinical applicability with additional efforts toward local delivery and
modification of synthetic bioprostheses.Vascular smooth muscle cell (SMC) migration, prolif-
eration, and matrix synthesis are the critical events in the
pathophysiology of intimal hyperplasia leading to arterial
restenosis after vascular injury.1-4 Invasive treatment of
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doi:10.1016/j.jvs.2003.12.0301074arterial stenoses causes intimal damage that initiates a cas-
cade of events that include thrombin production in high
concentrations at the injury site.5-8 Thrombin, the final prod-
uct of the coagulation cascade, cleaves fibrinogen to fibrin,
leading to thrombus formation. It is also a potent activator of
platelets, leading to their adhesion and subsequent degranu-
lation and aggregation. Activated platelets release a variety of
substances, such as platelet-derived growth factor, transform-
ing growth factor-, and thrombospondin, all of which
promote SMC migration, proliferation, and matrix produc-
tion, accelerating the process of restenosis.9-12 Thrombin
itself exerts a primary mitogenic effect on SMCs through
direct protease activated receptor–mediated stimulation.7
Therefore thrombin, both through its primary effects and
as the result of secondary events, has a critical role in the
initiation and development of intimal hyperplasia.
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membrane–expressed glycoprotein, has known anticoagu-
lant effects stemming from high-affinity inhibitory binding
with thrombin.13,14 The thrombomodulin-thrombin com-
plex prevents the ability of thrombin to protentiate clot
development, while at the same time it potently activates
the anticoagulant factor protein C.15-17 This suppresses the
secondary stimulation of platelet activation. In addition to
these well-established antithrombotic effects, thrombo-
modulin also has physiologic effects, evident at the cellular
level.18 This may be due to interference with the interaction
of thrombin with cell surface PAR receptors or through
internalization of the thrombin-thrombomodulin complex
activating intracellular mechanisms.7,18,19 Finally, throm-
bomodulin has potential to demonstrate an anti-inflamma-
tory effect, either through its N-terminal lectinlike moi-
ety20 or indirectly through the activation of protein C.21,22
This multiplicity of effects, along with thrombomodu-
lin being an endogenous glycoprotein present in the vessel
wall, makes it an attractive target to modify the response to
vascular injury. A recombinant soluble thrombomodulin,
lacking only the transmembrane and cytoplasmic tail do-
mains but retaining its O-terminal–linked oligosaccharide
and chondroitin sulfate moieties (antithrombin III binding
site), six epidermal growth factor–like segments (including
the functional thrombin and protein C binding sites), and
the terminal lectin homology domain, has been achieved
for experimental use.23-26 We have previously reported that
rTM inhibits thrombin-induced arterial SMC proliferation
in vitro.27 In the present study we sought to elucidate the
multipotential effect of rTM on neointimal hyperplasia in
vivo, using a rabbit femoral artery balloon injury model.
MATERIAL AND METHODS
This study was approved by The Animal Care and Use
Committee of the University of Massachusetts Medical
School. All animal procedures conformed to guidelines set
forth by the American Association for Accreditation of
Laboratory Animal Care and by the National Institutes of
Health publication No. 86-23, Guide for the Care and Use
of Laboratory Animals.28
Surgical procedure
Male New Zealand White rabbits (Millbrook Farm,
Amherst, Mass; average weight, 3.50 kg) were anesthetized
with intramuscularly administered ketamine (30 mg/kg)
and xylazine (4.5 mg/kg), and maintained with 1% to 2%
endotracheally administered isofluorane. Intravenous ac-
cess was achieved by cannulating an ear vein with a 24-
gauge angiocatheter. Five minutes before controlling the
superficial femoral artery blood flow, recombinant human
soluble thrombomodulin (rTM; TMD1(CS) rTM; Eli
Lilly & Co, Indianapolis, Ind) at 145 g/kg body weight,
corresponding to 2.0 g/mL in circulation, found to be
optimal on the basis of results of previous in vitro study,27
or Tris-hydrochloride (HCl) buffer (vehicle control) was
administered intravenously. No heparin or other anticoag-
ulant was administered. The superficial femoral artery wasdenuded with a 2F arterial embolectomy catheter (Baxter
Healthcare Corp, Irvine, Calif) through the superficial sa-
phenous artery. The balloon was inflated with 0.2 mL of
air, and withdrawn through the artery, three times. A 6-0
polypropylene suture was placed at the level of the proximal
clamp as a landmark. The animals were allowed to recover
under veterinary supervision, kept on standard feed and
water ad libitum, and given analgesic buprenorphine (0.03
mg/kg) subcutaneously every 8 hours for 48 hours.
The animals were randomly selected to receive rTM or
Tris-HCl buffer. For uniformity, matched rTM and buffer
control animals were treated on the same day under the
same conditions by the same surgical team. Two treatment
protocols were designed. In group A rTM or Tris-HCl
buffer control was administered intravenously on the day of
surgery 5 minutes before clamping and again after restora-
tion of limb flow. In group B the rabbits were treated
identically to those in group A with respect to perioperative
administration, but then received additional rTM or Tris-
HCl buffer twice a day for an additional 48 hours postop-
eratively. The rabbits were followed up at either 4 days or 1,
2, or 4 weeks postoperatively.
Specimen collection
Two rabbits were euthanized at 4 days for inspection of
the severity and uniformity of balloon injury and early
histologic appearance, 12 rabbits were euthanized at 7 days
for quantitative evaluation of inflammatory cell adhesion
and infiltration, and 70 rabbits were euthanized at 2 and 4
weeks for morphometric evaluation. On the day of termi-
nation, the animals were anesthetized and intubated with
the methods defined previously. Laparotomy was per-
formed, the aorta and vena cava were exposed, and the
aorta was cannulated. The animals were exsanguinated
through an incision in the vena cava, followed by antero-
grade perfusion of the aorta with 0.9% normal saline solu-
tion at 120 to 130 mm Hg pressure until the effluent was
clear. This was immediately followed by perfusion fixation
with 10% buffered formalin (for paraffin-embedding) or 4%
paraformaldehyde (for electron microscopy) at the same
pressure until the hind limbs were stiff. Segments of the
experimental arteries, including the common femoral, su-
perficial femoral, and popliteal arteries, were removed en
bloc. Each denuded superficial femoral artery sample (av-
erage length, 2.5 cm) was cross-sectioned into three seg-
ments, the proximal, middle, and distal thirds. The cross-
sectioned samples were then subjected to paraffin
embedding, microtome section (5 m) and hematoxylin-
eosin staining. Specimens were identified by corresponding
the rabbit identification number only, and all subsequent
analysis was performed in a blinded fashion without iden-
tification of the treatment group.
Pathologic evaluation
Histomorphometry. Two representative sections of
each cross-section segment (proximal, middle, distal) of
arterial samples (six per artery) were analyzed morpho-
metrically with a digital imaging computerized planimetry
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camera (Roper Scientific) attached to an inverted micro-
scope (Olympus IX-70), and analyzed with imaging meta-
morph software (Universal Imaging Corp, Downingtown,
Pa). The imaging system was calibrated with a stage micro-
meter, and the lumen, intima, media, or whole artery
measurements were obtained by manually tracing the areas
on the digital images. Parameters including the area ratios
of intima to media (I/M) and lumen to whole artery (L/A)
were calculated.
Inflammatory reaction. The cross-section samples of
arteries harvested 7 days after balloon injury were evaluated
for inflammatory cell adhesion and infiltration with light
microscopy, scanning electron microscopy (SEM) and
transmission electron microscopy (TEM), and immunohis-
tochemical and immunohistofluorescence staining with
monoclonal antibody to neutrophils and T cells or to
macrophages. The artery samples used for evaluation of
inflammatory reaction were patent specimens only; throm-
bosed arteries with obstructive or near obstructive clot were
excluded from this analysis.
Light microscopy. The inflammatory cells (neutrophils,
macrophages, monocytes) adherent to the denuded surface
or those infiltrated into the entire arterial wall of the prox-
imal, middle, and distal segments of the injured artery
stained with hemotoxylin-eosin were counted at400 and
1000 magnification to identify the cell types, if needed.
Immunohistochemical or immunohistofluorescence
staining. Representative cross-section samples from the
middle segment of the 7-day post–balloon-injured artery
were processed for immunohistostaining with either a pri-
mary monoclonal antibody to rabbit neutrophils and T cells
or a monoclonal antibody to macrophages, to identify
specific cell types and confirm findings at hematoxylin-
eosin staining.
Neutrophils and T cells were identified with monoclo-
nal mouse anti-rabbit neutrophils and T-cell antibody
MAC805 (Serotec, Raleigh, NC). Before staining, tissue
sections were deparaffinized, dehydrated with xylene, and
rehydrated through graded series of alcohols, then heated
Morphometric findings in rabbit femoral artery after balloo
Sample
Lumen area
(mm2)
2 wk 4 wk
Group A (1-day IV)
Tris-HCI 0.98  0.07 0.63  0.10 0.
rTM 0.55  0.07 0.59  0.07 0.
P .
Group B (3-day IV)
Tris-HCI 0.96  0.09 1.02  0.06 0.
rTM 1.10  0.06 0.85  0.09 0.
P .
Arteries with obstructive thrombus with or without complete occlusion we
Number of arteries (R  L). Group ABuffer: 2 wk, 9; 4 wk, 6. rTM:2 wk
I/M, Intima-media ratio; L/A, lumen–whole artery ratio; rTM, recombinanat 95°C to 99°C in Target Retrieval Solution (DAKO,
Carpinteria, Calif) for 30 minutes, for antigen retrieval. We
used 10% goat serum to block the nonspecific binding for 1
hour at room temperature, and the primary mouse anti-
rabbit antibody MAC805 was applied to the sections and
incubated at 4°C overnight. The sections were then incu-
bated with either streptavidin-peroxidase for 15 minutes,
and visualized by a “positive” chromatic color change with
3,3-diaminobenzidine (DAB) plus substrate-chromogen
(diaminobenzidine-chromogen solution) under light mi-
croscopy or with a Rhodamine Red-X–conjugated Affi-
niPure goat anti-mouse immunoglobulin G (Jackson Im-
muno Research Laboratories, West Grove, Pa) second
antibody, and evaluated with fluorescence microscopy.
Macrophages were identified with techniques similar to
those described above, with the mouse anti-rabbit macro-
phage monoclonal biotinylated primary antibody RAM11
(DAKO). Macrophages were visualized by chromatic color
change with DAB plus substrate-chromogen under light
microscopy.
SEM and TEM. Cross-sections from the middle seg-
ment of the 7-day post-injury arterial samples were submit-
ted for SEM and TEM evaluation. The samples for SEM
evaluation were fixed in situ by perfusion with 4% parafor-
maldehyde, followed by immersion fixation in 2.5% (vol/
vol) glutaraldehyde, washed in phosphate-buffered saline
solution (PBS), and dehydrated through a graded series of
ethanol concentration to 100% and critical-point dried in
carbon dioxide. The samples were mounted onto alumi-
num stubs with silver conductive paste, sputter coated with
gold/palladium, and examined with an autoscan SEM
(ETEC Corp, Hayward, Calif) at 20-kV accelerating
voltage.29,30
For TEM examination, pieces of the perfusion fixed
arteries were placed in 2.5% (vol/vol) glutaraldehyde and
washed in PBS. The samples were post-fixed in 1% osmium
tetroxide, washed in PBS, and dehydrated through a
graded series of ethanol to 100%, transferred through pro-
pylene oxide, and finally into a 50:50 (vol/vol) mixture of
propylene oxide–epoxy resin (LX 112/Araldite 502), and
gioplasty
Neointima area
(mm2)
Media area
(mm2)
wk 4 wk 2 wk 4 wk
0.08 0.39  0.02 0.39  0.06 0.26  0.02
0.04 0.25  0.02 0.26  0.05 0.25  0.01
.0001
0.03 0.34  0.02 0.27  0.02 0.21  0.01
0.02 0.26  0.03 0.32  0.02 0.23  0.02
.0001
uded from morphometric analysis.
wk, 10. Group BBuffer: 2 wk, 7; 4 wk, 4. rTM:2 wk, 9; 4 wk, 7.
mbomodulin.n an
2
34 
15 
0001
26 
16 
0001
re excl
, 10; 4
t thro
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placed in fresh full-strength epoxy resin, then placed in flat
embedding molds filled with fresh resin mixture, and poly-
merized overnight at 70°C. Once the blocks were polymer-
ized, the arterial samples were cut out, reoriented, and
attached to a plastic support with adhesive. The arterial
samples were ultrathin sectioned (70 nm thick) on a
Reichert-Jung Ultra-cut E with a diamond knife. Sections
were collected on copper support grids, exposed to lead
citrate and uranyl acetate contrast, and examined with a
Philips CM 10 TEM at 80 kV.
Statistical analysis
The data were analyzed with the SAS Proc Mixed
Procedure (SAS, Cary, NC).31,32 Compliance with the
assumption of normality for the distribution of residuals
was evaluated graphically with frequency histograms and
with the Kolmogorov-Smirnov goodness of fit test.33 Dif-
ferences were considered significant at the 95% confidence
level (P  .05).
The results of lumen area, neointima area, media area,
whole artery area, I/M ratio, and L/A ratio are expressed as
mean  SEM of four individual experimental groups, each
with four or five animals, representing eight to 10 arteries,
with six representative cuts per artery. The effects of ratios
versus rabbit limb (left, right), artery segment (proximal,
middle, or distal third), treatment (rTM, Tris-HCl buffer),
treatment duration (1 or 3 days), and duration of follow-up
(2 or 4 weeks) were evaluated with analysis of variance for
mixed models.31
Analysis of the proportion of rabbits with thrombosis
was modeled with logistic regression analysis.34 Interac-
tions between study factors were modeled; however, be-
cause of empty cells “zero,” some estimates were ill-condi-
tioned, and a stratified analysis approach was taken. Relative
risk estimates across strata, defined as all combinations of
study design factors, were made with the Mantel-Haenszel
odds ratio estimator and evaluated with the Mantel-
Haenszel 	2 test.35 The resulting estimates were compared
directly and by comparing exact confidence interval esti-
mates36 with possible and Cornfield confidence intervals35
when exact intervals were not possible.
Table continued
Whole artery area
(mm2)
2 wk 4 wk 2 wk
1.71  0.20 1.28  0.10 0.78  0.04
0.84  0.10 1.10  0.09 0.57  0.05
.0001
1.49  0.09 1.57  0.08 1.10  0.08
1.58  0.08 1.28  0.14 0.47  0.05
.0001In analysis of inflammatory reaction, differences be-
tween treatments were evaluated with mixed-model analy-
sis of variance,37 in which rabbit, side, and sample section
were included as random effects, and treatment and day
were considered fixed effects. Compliance with the normal-
ity assumption was evaluated with the Kolmogorov-Smir-
nov test for normality.33
RESULTS
Rabbits
Eighty-four rabbits were used for this study. The aver-
age body weight of group A (1-day treatment group) was
3.50 0.30 kg (rTM) and 3.48 0.32 kg (control), and of
group B (3-day treatment group) was 3.48  0.30 kg
(rTM) and 3.42  0.20 kg (control). There was no signif-
icant difference in body weight between any of the groups.
Histologic analysis
The histologic appearance of representative cross-sec-
tions of the rabbit superficial femoral artery are shown in
Fig 1. The normal superficial femoral artery has a mono-
layer of endothelium (Fig 1, A, B). At 4 days after balloon
angioplasty both the buffer control group (Fig 1, C) and
the rTM infusion group (Fig 1, D) showed that the endo-
thelium was completely depleted, the internal elastic lamina
was interrupted, and SMCs in the media were severely
damaged. There was more nuclei staining, mostly of in-
flammatory cells adherent to the injured arterial surface and
that infiltrated into the media. This inflammatory reaction
was suppressed after intravenous rTM administration (Fig
1, D). Aggressive neointimal growth was present at 2 weeks
after balloon injury (Fig 1, E). This again was significantly
inhibited with systemic rTM administration (Fig 1, F).
Thrombus formation
For overall analysis, thrombus was defined as either a
thin layer of mural thrombus or obstructive luminal clot,
with or without complete arterial occlusion. In the buffer
control group thrombus was found inside the femoral
artery specimens at harvest in 20% (two of 10; one mural
thrombus, one obstructive clot) at 2 weeks and 25% (two of
L/A
4 wk 2 wk 4 wk
1.58  0.08 0.61  0.02 0.44  0.05
0.96  0.08 0.67  0.02 0.51  0.03
.0001
1.65  0.09 0.62  0.04 0.62  0.01
1.15  0.08 0.70  0.02 0.64  0.02
.0001I/M
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presence of thrombus of 22%. In group B control animals,
thrombus was identified in 40% (four of 10; obstructive
clot) at 2 weeks and 33% (two of six; obstructive clot) at 4
weeks, for an overall thrombus rate of 38%. After rTM
treatment, all arteries in group A were free of thrombus. In
group B, one artery demonstrated clot in the lumen, with-
out obstruction, at 2 weeks (one of 10), and one had mural
thrombus at 4 weeks (one of eight). There was a significant
effect of rTM treatment (P 
 .012), with arteries in the
buffer control group 8.1 times as likely to clot than those in
the rTM group (95% confidence interval, 1.577-41.667).
No significant effect of duration of treatment or of fol-
low-up was found. True thrombotic occlusion was ob-
served in nine of 34 control arteries (26.5%), and only one
of 38 arteries in the rTM group (2.6%).
A summary of morphometric findings in all groups at all
time points is presented in the Table. Data from the artery
specimens with obstructive luminal clot were excluded
Fig 1. Microphotographs of cross-section of rabbit fem
injury in buffer control group (C) and rTM infusion gro
and rTM group (F) (hematoxylin-eosin; original magnififrom analysis for neointimal hyperplasia and inflammatory
reaction.
Neointima formation
Neointima formation was evaluated on the basis of
absolute neointima area, I/M ratio, and L/A ratio (Fig 2;
Table).
Neointima area. The neointima area of arteries in the
buffer control group was increased from 2 weeks to 4 weeks
by 15% in group A and 31% in group B (P  .0001). This
pathologic formation was significantly suppressed with in-
travenous rTM treatment by 56% at 2 weeks and 36% at 4
weeks (P  .0001). In group B (3-day treatment) rTM
infusion decreased the neointima area by 39% at 2 weeks
and 24% at 4 weeks (P  .0001). The effect of rTM
treatment did not depend on the duration (1 day vs 3 days),
follow-up (2 weeks vs 4 weeks), side (left vs right), or
segment (proximal, middle, distal) of the artery.
artery show normal artery (A, B), 4-day post–balloon
), and 2-week post–balloon injury in control group (E)
n 5 and 25).oral
up (D
catio
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I/M ratio increased 103% between the 2-week and 4-week
samples. With intravenous rTM treatment the I/M ratio
was significantly decreased compared with that of buffer
control in all treatment duration and follow-up groups (P
 .0001). Specifically, with 1-day rTM infusion, intimal
hyperplasia was inhibited by 27% at 2 weeks and 39% at 4
weeks (P  .0001). With 3-day treatment rTM infusion
suppressed the I/M ratio by 57% at 2 weeks and 30% at 4
weeks, as compared with control group (P  .0001). The
treatment effect did not vary with duration, side, or seg-
ment of the artery (Fig 2, A). In groups A and B the relative
increase in neointimal area and even in I/M ratio between
2 and 4 weeks appears greater for the rTM group; however,
there was no statistical significance (P 
 .6105).
Lumen area. There was no significant difference in
lumen area between buffer control and rTM treatment
groups (P 
 .951). However, a significant effect of dura-
tion was observed. With 3-day rTM infusion the lumen area
at both 2 weeks and 4 weeks was significantly increased
compared with that of 1-day treatment (P 
 .009).
Whole artery area. The mean whole artery area in
buffer control group specimens was statistically larger than
that in the rTM infusion group (P 
 .045). No significant
differences were found between 1-day and 3-day treatment
Fig 2. Neointima of cross-section of balloon-injured rabbit fem-
oral artery stained with hematoxylin-eosin. Degree of neointima
was measured with digital imaging computerized planimetry, and
calculated according to intima-media ratio (A) and lumen–whole
artery ratio (B). P .0001, recombinant thrombomodulin (rTM)
vs control, 4 vs 2 weeks (A).duration, 2-week and 4-week follow-up, and anatomic side
and segment of the artery.
L/A ratio. The L/A ratio was evaluated as an indica-
tor of preservation (conversely, stenosis) of arterial lumen
area. rTM infusion increased the L/A ratio in all treatment
duration and follow-up groups. Compared with control
groups, use of rTM increased the L/A ratio 10% and 13% at
2 weeks, and 16% and 3% at 4 weeks, in groups A and B,
respectively. These results, however, did not reach statisti-
cal significance (Fig 2, B).
Inflammatory reaction
Quantitation of inflammatory cell adhesion and infiltra-
tion in the balloon-injured arteries is exhibited in Fig 3. At
7-days after injury an inflammatory reaction induced by the
injury process was still evident. In control artery specimens
the inflammatory cells included neutrophils, macrophages,
and T cells adherent to the arterial lumen wall, with signif-
icant infiltration into the media. Intravenous administration of
rTM reduced the acute inflammatory infiltration of neutrophil
number from 32 6 to 11 3 and from 21 5 to 12 4 in
groups A and B, respectively. This finding approached
statistical significance (P 
 .0675). No significant effects
were found for macrophages and T cells. No adherent T
cells were observed in any sample. These findings were
confirmed with cell-specific immunohistostaining (Fig 4).
SEM and TEM findings
In the 1-day treatment group, samples taken from 7-day
post-injury control arteries submitted to SEM showed obvi-
ous clotting with platelets and thrombus formation, and in-
flammation with neutrophils and macrophages adherent to
the denuded artery surface (Fig 5, A). Similar samples from
the rTM-treated group demonstrated some platelet adhe-
sion, but were clear of thrombus, and showed few scattered
neuptophils (Fig 5, B). In the 3-day treatment groups the
differences between the rTM treatment and the buffer control
groups was pronounced. At SEM, whereas the buffer-treated
artery showed heavy clotting and platelet adherence, and the
appearance of numerous white blood cells attached to the
luminal surface (Fig 6, A), the rTM-treated artery appeared
relatively clear and free of thrombus, with very few platelets
attached to the damaged luminal surface (Fig 6, C). When
viewed at TEM the difference was even more dramatic. The
buffer-treated arterial surface had numerous platelets ad-
hered directly to the exposed surface of the internal elastic
lamina, and a polymophonuclear leukocyte present at the
junctions of internal elastic lamina (Fig 6, B). The rTM-
treated arterial segments appeared clear of platelets and
blood cells, although the endothelium was completely
gone, and areas of internal elastic lamina had been eroded,
exposing the laminar structure (Fig 6, D).
DISCUSSION
Since the endothelium and its expression of thrombo-
modulin are lost after arterial injury, restoration or replace-
ment of this glycoprotein should suppress the trauma-
induced events that ultimately lead to thrombosis and
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the rabbit femoral artery was depleted after balloon catheter
injury, as demonstrated at light and electron microscopy.
The media SMCs were severely damaged, and portions of
the internal elastic lamina are interrupted, as seen in the
4-day and 7-day postoperative samples. Thrombus forma-
tion was also readily apparent in the control arteries at these
early time points. Inflammatory cells adherent to the de-
nuded luminal surface, and infiltrated into the media, were
still prominent in the 7-day post–balloon-injured arteries.
Neointimal formation became obvious at 2 weeks, and was
dramatic by 4 weeks after balloon injury. Previous in vitro
study in our laboratory demonstrated that rTM at a con-
centration of 2g/mL inhibited arterial SMC proliferation
induced by -thrombin at a concentration of 0.25 to 3
U/mL.27 The results of the current study demonstrate that
rTM administered intravenously at the same concentration
exhibited an in vivo effect by significantly inhibiting throm-
Fig 4. Representative immunohistochemical and imm
balloon injured rabbit femoral arteries. Neutrophils are
developed with DAB stain (left images) or rhodamine
human thrombomodulin–treated arteries (B). Similar
shown).
Fig 3. Inflammatory cell adhesion and infiltration at 7 da
cells were counted in cross sections of three segments (pro
hematoxylin-eosin, with light microscopy at 400 an
infiltration are depicted as mean  SEM. rTM, Recombbosis and neointimal hyperplasia after balloon injury. The
latter was most apparent with reduction in the conventional
measure for intimal hyperplasia, the I/M ratio.
Lumen restenosis is the net result of intimal hyperplasia
and arterial remodeling, and it remains to be shown which
of these two determinants is most closely related to long-
term angiographic or clinical treatment failure. Attempts to
define lumen preservation pathologically have proved more
difficult in fixed specimens. No significant difference in
lumen area or L/A ratio was found between the treatment
groups in this study. There are several possible explana-
tions. First, for technical reasons, lumen area can be variable
on histologic specimens, because it is susceptible to subtle
differences in fixation pressure and specimen embedding
and cutting. The parameters of lumen area and L/A ratio
are more accurate with in vivo quantitative angiography or
intravascular ultrasound measurement,38-42 but less reli-
able on retrieved fixed paraffin section samples.
istofluorescence stained cross sections of 7-day post–
tified with monoclonal antibody MAC805. Color was
ight images) for control arteries (A) and recombinant
es were obtained after staining for macrophages (not
st–balloon injury in rabbit femoral artery. Inflammatory
l, middle, distal) of six arteries in each group stained with
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Volume 39, Number 5 Li et al 1081Second, it was apparent that the arteries, particularly in
the control group, exhibited significant remodeling in re-
sponse to injury and subsequent intimal hyperplasia forma-
tion. The contribution of arterial remodeling in restenosis
after angioplasty is unclear. Studies after angioplasty of
minipig coronary and rabbit peripheral arteries have shown
that constructive remodeling is a major contributor to
restenosis, suggesting collagen accumulation as one poten-
tial factor.38-41 However, Gertz et al42 reported a study in
atherosclerotic rabbit femoral arteries in which they found
no arterial remodeling after angioplasty. On the basis of
correlative angiographic and histomorphometric evidence,
these authors concluded that geometric remodeling is not
the principal pathogenetic process in restenosis. In this
study the mean whole artery area in the control group was
Fig 5. Representative scanning electron microphotogr
femoral arteries in 1-day treatment group. Buffer contro
treated arteries (B) (original magnification 1000.)
Fig 6. Representative scanning electron microscope (A,
tographs of cross sections of 7-day post–balloon-injur
control arteries (A,1000; B,15,000) versus recombi
15,000).statistically larger than that in the rTM treatment group,
consistent with compensatory enlargement in response to
more significant intimal hyperplasia. By inhibiting intimal
hyperplasia, rTM appears to alter arterial remodeling, with
less vessel dilatation in response to less neointima forma-
tion. At these early time points, this resulted in lack of
significant difference in lumen area or L/A ratio between
treatment groups. As intimal hyperplasia progresses in the
control group, however, lumen area may eventually be lost
when the artery reaches maximal dilatation.
We have begun to understand the optimal delivery for
thrombomodulin. This study compared perioperative ad-
ministration and extended treatment over 72 hours. Pro-
longed treatment did not seem to offer significant advan-
tage. This suggests that the critical time point for
of cross section of 7-day post–balloon-injured rabbit
ries (A) versus recombinant human thrombomodulin–
nd transmission electron microscope (B, D) micropho-
bbit femoral arteries in 3-day treatment group. Buffer
uman thrombomodulin–treated arteries (C,1000; D,aphs
l arteC) a
ed ra
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May 20041082 Li et althrombomodulin activity is at the time of injury or in the
very early stages after injury. This may make intuitive sense,
because balloon angioplasty depletes the endothelium and
damages the artery wall, resulting in immediate thrombin
production in high concentrations.5,8 If the critical func-
tional mechanism of thrombomodulin action relies on its
high-affinity binding with and inhibition of thrombin,13-15
then thrombomodulin must be present with the arrival of
thrombin. This enables the immediate conversion of
thrombin’s procoagulant and mitogenic properties to anti-
coagulant and antimitogenic properties before significant
pathophysiologic processes are initiated.15-17 Such a lim-
ited and focused approach, however, may simply delay the
pathologic process and not provide durable long-term re-
sults. There was some suggestion of this “catch-up” phe-
nomenon occurring in the thrombomodulin treatment
group, although this did not reach statistical significance.
Recent development and application of new antithrom-
botic drugs, including low molecular weight heparins,
thrombin antagonists such as hirudin and its analogs, and
argatroban, have greatly expanded this field of study.43 We
did not directly compare the antithrombotic, antihyper-
plastic, and anti-inflammatory effects of thrombomodulin
with those of any of these alternative thrombin inhibitors in
this study. Although heparin is a potent inhibitor of SMC
growth and intimal hyperplasia in some animal models, it
has been ineffective in inhibiting restenosis in studies both
animal44 and human. Other studies have demonstrated
varying results with use of hirudin45-50 and argatroban51-53
with respect to their effects on SMC physiology and inflam-
mation in vitro or in the setting of arterial injury. Most
show some promise, but are limited solely to the effects
resulting from thrombin inhibition. Thrombomodulin, be-
cause of its central role as an endogenous catalyst to the
interaction of thrombin, antithrombin III, and protein C,
offers additional potential, compared with direct thrombin
inhibition alone. Much of its effect may result from its
ability to inhibit thrombin, but through direct cellular
effects on SMCs and the activation of protein C, thrombo-
modulin also demonstrates antiproliferative and anti-in-
flammatory effects. The anti-inflammatory effect may sim-
ply be related to prevention of clot formation and its potent
inflammatory reaction. However, the anti-inflammatory
effect was seen in the absence of thrombosis. It likely also
involves a direct effect of thrombomodulin from its N-
terminal lectinlike domain, which causes downregulation
of expression of inflammatory cell adhesion molecules (in-
tercellular adhesion molecules, selectins), leading to less
inflammatory cell adhesion and infiltration and less inflam-
matory cytokine release.20 In addition, activation of protein
C by thrombomodulin could lead to additional anti-inflam-
matory effect.21 To take advantage of these additional
effects of thrombomodulin, more controlled and perhaps
localized delivery will likely provide effective and durable
results. Initial evaluation of possible delivery modes is un-
derway, and the long-term experimental outcomes from
these early inhibitory effects on intimal hyperplasia warrant
further study.Restenosis is a substantial problem after angioplasty
and arterial reconstructive surgery.1,54 rTM administered
intravenously effectively inhibited neointima formation in a
balloon-injured small-caliber artery model. Decreasing
neointimal hyperplasia by 20% to 30% in a small-caliber
artery would significantly improve blood flow and improve
results of intervention. By virtue of its ability to inhibit
procoagulant, mitogenic, and inflammatory processes at
the site of injury, thrombomodulin may prove to be an
exciting and beneficial therapeutic agent in preventing ar-
terial thrombosis and restenosis after angioplasty and arte-
rial reconstruction.
We thank Lilly Research Laboratories for their gener-
ous gift of recombinant human thrombomodulin; and Jef-
frey A. Nickerson, PhD, Assistant Professor of Cell Biology,
University of Massachusetts Medical School, for his exper-
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